參考文獻 - 樟芝子實體與菌絲體對預防阿茲海默症之功效探討

王伯徹、黃仁彰 2002 靈芝與樟芝之研發與是場面面觀，食品工業 349(5): 3-17。

白佳真 2003 樟芝免疫調節蛋白與超氧歧化酶之研究，國立台灣海洋大學生物科技研究所碩士論文。

呂美津 2003 牛樟菇子實體乙醇萃取物誘導 HL60 細胞凋亡之研究，國立屏東科技大學熱帶農業研究所碩士論文。

宋祖瑩 2003 樟芝深層培養液抗氧化及抗腫瘤特性之研究，國立中興大學食品科學研究所博士論文。

李學勇，1990，基礎植物學，台北市，國立編譯館

沈立言 2001 牛樟芝菌絲體發酵萃取液對肝臟生理機能性之影響，90 年度保健食品研究開發計畫期中報告: 191-198。

沈立言 2002 牛樟芝菌絲體發酵萃取液對正常人肝、腎功能及生活品質之影響，

行政院國家科學委員會91 年度保健食品研究開發計畫報告。pp.28-34。

沈立言、馬良瑩、郭憲文、張永賢、陳昇明 2003 牛樟芝菌絲體發酵過濾液對正常人肝、腎機能與生活品質之影響，台灣保健食品學會年會。台北。

沈立言、陳怡欣、林文川 2001 牛樟芝菌絲體發酵過濾液對肝臟生理機能性之影響，中華民國食品科學技術學會年會。嘉義市。

沈立言、陳怡欣、林文川 2002 牛樟芝菌絲體發酵過濾液對大白鼠經四氯化碳誘導慢性肝損傷病理變化之影響，功能（保健）食品科技與發展國際研討會。

西安、中國。

易希珍 1976 普通植物學。台北市。環球出版社。

林金鑫、曾虹萍、陳勁初、蔡明憲、楊明芬、陳巧文 2001 大鼠致畸測一樟芝發酵原液凍乾成品，中華保健食品學會第二屆第一次會員大會。

林豔琪 2005 樟芝固態培植體之成分分析及功能性評估，私立南台科技大學生物科技研究所碩士論文。

高曉薇 1991 台灣靈芝屬新種樟芝之三帖類成分研究，台灣醫學院天然物醫學研究所碩士論文。

張中姿 2002 樟芝菌絲體之甲醇萃取部分對人類肝癌細胞株 (HepG2) 生長抑制作用的機轉探討，國立台灣大學醫學院生物化學暨分子生物學研究所碩士論文。

張怡婷 2004 樟芝抗腫瘤活性之研究，國立成功大學藥理學研究所碩士論文。

張東柱、謝煥儒、張瑞璋、傅春旭 1999 台灣常見樹木病害。台北市。行政院農業委員會出版社。

- 99 -

曹巧吟 2003 樟芝中免疫調節蛋白的純化與其生理活性之探討，國立台灣大學園藝學研究所碩士論文。

許勝傑、鍾煒惠、陳勁初、蔡明憲、王聖耀、蔡慶龍、陳巧文 2001 大白鼠口服高劑量樟芝菌絲體之急性毒性試驗，中華保健食品學會第二屆第一次會員大會。

陳怡欣 2002 牛樟芝發酵過濾液對大白鼠肝臟生理機能之影響，中國醫藥學院營養研究所碩士論文。

陳勁初、呂鋒洲 2001 靈芝之王 : 台灣樟芝元氣齋出版社台北、台灣。

陳勁初、林文鑫、陳清農、許勝傑、黃仕政、陳炎鍊 2001 台灣特有真菌-樟芝菌絲體之開發。Fung. Sci., 16: 7-22.

陳啟楨、蘇慶華、藍明煌 2001 樟芝固體栽培及其生物活性之研究。Fung. Sci., 16:

65-72.

郭淑卿 2002 樟芝發酵液對大鼠肝臟纖維化及胃腸功能之改善作用，中國醫藥學院中國藥學研究所藥學碩士論文。

陳清農、林文鑫、盛莉莎、黃仕政、陳勁初、劉宗榮 2001 樟芝對 Sprague-Dawley 大白鼠之連續投藥口服急性毒性，中華保健食品學會第二屆第一次會員大會。

黃坤正、丁懷謙、余俊強、何漣漪 2000 計畫標號：007051-04:3-12 基因毒理與動物病理組織之系統分析，依「食品新興製造系統整合及關鍵技術發四年計劃(第四年度)」。

黃鈴娟 2000 樟芝與姬松茸之抗氧化性質及其多醣組成分析，國立中興大學食品科學研究所碩士論文。

楊書威 1991 中藥樟菇活性成分之研究，國立台灣大學藥學研究所碩士論文。

楊新玲 2001 樟芝對人體臍帶血管內皮細胞之影響及作用之探討，行政院國家科學委員會九十年度保健食品研究開發計畫。

臧穆、蘇慶華，1990，我國台灣產靈芝屬新種-樟芝 (型態、定名)，雲南植物研究所：12(4), 395-6。

劉俊仁 2003 中草藥抗癌機制研究(壹):黃芩素及黃苓苷對血管新生作用之影響及其機制探討；(貳):樟芝活性多醣體之生物活性分析及其經由免疫調節抑制腫瘤生長之研究，國立台灣大學生物化學暨分子生物學研究所博士論文。

蔡雁暉 2002 樟芝深層培養液及其多醣體之抗氧化特性，國立中興大學食品科學研究所碩士論文。

戴宇昀、蕭學民、蔡金川、陳勁初、黃仕政，胡淼琳 2001 樟芝子實體對酒精誘發急性肝損傷之保肝功能評估，中華保健食品協會第二屆第一次會員大會。

- 100 -

魏佳瑜 2003 固體栽培樟芝甲醇萃取物抗變異自由基功效與抗血小板凝集作用探討，私立台北醫學大學公共衛生系碩士論文。

蘇慶華 2002 健康的守護神-國寶樟芝，愛克思文化事業有限公司。台灣。

騰長青 1999 阿茲海默症臨床症狀概述，老年醫學與保健。5: 15-16.

Abraham CR, Selkoe DJ, Potter H, Price DL, Cork LC. 1989. Alpha 1-antichymotrypsin is present together with the beta-protein in monkey brain amyloid deposits. Neuroscience. 32:715-720.

Agca C, Fritz JJ, Walker CLary, Levey IA, Chan WA, Lah JJ, Agca Y. 2008. Development of transgenic rats producing human β -amyloid precursor protein as a model for Alzheimer's disease: Transgene and endogenous APP genes are regulated tissue-specifically. BMC Neuroscience.

9:28-40.

Akama KT, Albanese C, Pestell RG, Van Eldik LJ. 1998. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci USA. 95:5795-5800.

Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. 2001. Protein oxidation in the brain in Alzheimer’s disease. Neurosci. 103: 373-383.

Aloisi F. 1999. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv Exp Med Biol. 468: 123-133.

Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. 1995. An English translation of Alzheimer's 1907 paper, Uber eine eigenartige Erkankung der Hirnrinde. Clin Anat. 8:429-431.

Amos LA. 2004. Microtubule structure and its stabilisation. Org Biomol Chem. 2 (15):2153-2160.

Andreadis A, Brown WM, Kosik KS. 1992. Structure and novel exons of the human tau gene. Biochemistry. 31 (43):10626-10633.

Arai K, Matsuki N, Ikegaya Y, Nishiyama N. 2001. Deterioration of spatial learning performances in lipopolysaccharide-treated mice. Jpn J Pharmacol.

87(3):195-201.

Arnold CS, Johnson GV, Cole RN, Dong DL, Lee M, Hart GW. 1996. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem. 271 (46):28741-28744.

- 101 -

Arts IC, Hollman, PC. 2005. Polyphenols and disease risk in epidemiologic studies.

Am J Clin Nutr. 81: 317S–325S.

Arvin B, Neville LF, Barone FC, Feuerstein GZ. 1996. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev. 20:445-452.

Avila J, Pérez M, Lucas JJ, Gómez-Ramos A, Santa María I, Moreno F, Smith M, Perry G, Hernández F. 2004. Assembly in vitro of tau protein and its implications in Alzheimer's disease. Curr Alzheimer Res. 1 (2):97-101.

Ballatore C, Lee VM, Trojanowski JQ. 2007. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 8 (9):663-672.

Blass JP. 2001. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res. 66:851-856.

Blennow K, de Leon MJ, Zetterberg H. 2006. Alzheimer's disease. Lancet. 9533:

387-403.

Bowen DM, Smith CB, White P, Davison AN. 1976. Neurotransmitter- related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain.

99: 459-496.

Boyd E. 1935. The growth of the surface area of human body: University of Minnesota Press.

Braak H, Braak E, Grundke-Iqbal I, Iqbal K. 1986. Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett. 65 (3):351-355.

Bullido M. J, Valdivieso F. 2000. Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease. Microsc Res Tech. 50 : 261-267.

Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. 1993. Generation of beta- amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci USA. 90 (5): 2092-2096.

Butterfield DA, Drake J, Pocernich C, Castegna A. 2001. Evidence of oxidative damage in Alzheimer’s disease brain：central role for amyloid β peptide. Trends Mol Med. 7：548-554.

Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D. 2005. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 25 (40):9096-9101^.

- 102 -

Buxbaum JD, Choi EK, Luo Y, Lilliehook C, Crowley AC, Merriam DE, Wasco W.

1998. Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat Med. 4(10):1177-81.

Cai XD, Golde TE, Younkin SG. 1993. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 259: 514-516 Casanova MF, Troncoso JC. & Price DL. 1986. Hematogenous origin of brain

macrophages: a case report. Neurology. 36: 844-847.

Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. 1992. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 360: 672-674.

Citron M. 2004. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci. 5 (9): 677-685.

Chang TT, Chou WN. 1995. Antrodia camphorata sp.Cinnmomum Kamehirai in Taiwan. Mycol. Res. 99:756-758.

Chao CC, Hu S, Ehrlich L, Peterson PK. 1995. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun. 9: 355-365.

Chen CC, Shiao YJ, Lin RD, Shao YY, Lai MN, Lin CC, Ng LT, Kuo YH. 2006.

Neuroprotective diterpenes from the fruiting body of Antrodia camphorata. J Nat Prod. 69:689-691.

Chen CH, Yang SW. 1995. New steroid acid from Antrodia xinnamomea a fungal parasite of Cinnanomun micranthum. J. Nat. Prod. 58:1655-1661.

Chen J, Buchanan JB, Sparkman NL, Godbout JP, Freund GG, Johnson RW. 2008.

Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav Immun.

22(3):301-311.

Cheng JJ, Yang CJ, Cheng CH, Wang YT, Huang NK and Lu MK. 2005.

Characterization and Functional Study of Antrodia camphorata Lipopolysaccharide. J Agric Food Chem. 53:469-474.

Cherng IH, Chiang HC, Cheng MC, Wang Y. 1995. Three new triterpenoids from Antrodia cinnamomea. J. Nat. Prod. 58:365-371.

Cherng IH, Wu DP, Chiang HC. 1996. Triterpenoids from Antrodia

cinnamomea. Phytochem. 41: 263-267.

- 103 -

Chiang HC, Wu DP, Cherng IH, Ueng CH. 1995. A sesquiterpene lactone, phenyl and biphenyl compounds from Antrodia cinnamomea. Phytochemistry. 39: 613-616.

Chien SC, Chen ML, Kuo HT, Tsai YC, Lin BF, Kuo YH. 2008. Anti-inflammatory activities of new succinic and maleic derivatives from the fruiting body of

Antrodia camphorata. J Agric Food Chem. 56:7017-7022.

Chihara, G 1992. Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Dev Biol Stand. 77: 191–197.

Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA. 2004. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann N Y Acad Sci. 1035:68-84.

Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. 2000. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 20:558-567.

Coria F, Castaño EM, Frangione B. 1987. Brain amyloid in normal aging and cerebral amyloid angiopathy is antigenically related to Alzheimer's disease beta-protein.

Am J Pathol. 129(3):422-428.

Curran BP, O'Connor JJ. 2003. The inhibition of long-term potentiation in the rat dentate gyrus by pro-inflammatory cytokines is attenuated in the presence of nicotine. Neurosci Lett. 344(2):103-106.

Cushnie TPT, Lamb AJ. 2005. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 26 (5): 343–356.

Darvesh S, Martin E, Walsh R, Rockwood K. 2004. Differential effects of lipid-lowering agents on human cholinesterases. Clin Biochem. 37:42-49.

Deng JY, Chen SJ, Jow GM, Hsueh CW, Jeng CJ. 2009. Dehydroeburicoic Acid Induces Calcium- and Calpain-Dependent Necrosis in Human U87MG Glioblastomas. Chem. Res. Toxicol. 22:1817-1826.

DiPatre PL, Gelman BB. 1997. Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. J Neuropathol Exp Neurol. 56: 143-149.

Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, et al. 2001. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56:

- 104 -

1154-1166.

Esler WP, Wolfe MS. 2001. A portrait of Alzheimer secretases--new features and familiar faces. Science. 293:1449-1454.

Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. 2006.

Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett. 399:91-95.

Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT, Jr. 1995.

Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.

Proc Natl Acad Sci USA. 92:763-767.

Flood JF, Morley JE, Roberts E. 1991. Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer disease. Proc Natl Acad Sci USA. 88:3363-3366.

Frei B. 2009. Controversy: What are the true biological functions of superfruit antioxidants?. Nutraceuticals World.Retrieved February 5, 2010.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, et al. 2005. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 64: 1553-1562.

Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo YM, Roher AE. 1996. Specific domains of β-amyloid from Alzheimer plaque elict neuron killing in human microglia. J.

Neurosci. 16:6021-6037.

Glenner GG, Wong CW. 1984. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 120:885-890.

Goedert JJ, Mendez H, Drummond JE, Robert-Guroff M, Minkoff HL, Holman S, Stevens R, Rubinstein A, Blattner WA, Willoughby A, et al. 1989.

Mother-to-infant transmission of human immunodeficiency virus type 1:

association with prematurity or low anti-gp120. Lancet. 2 (8676):1351-1354.

Golde TE. 2003. Alzheimer disease therapy: can the amyloid cascade be halted?. J Clin Invest. 111:11-8.

Gong CX, Iqbal K. 2008. Hyperphosphorylation of microtubule-associated protein tau:

a promising therapeutic target for Alzheimer disease. Curr Med Chem. 15:

- 105 -

2321-2328.

Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F, Sisodia SS, Greengard P, Xu H. 1999. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci U S A. 96: 742-747.

Grutzendler J, Morris JC. 2001. Cholinesterase inhibitors for Alzheimer's disease.

Drugs. 61:41-52.

Gudasheva TA, Konstantinopol'skii MA, Ostrovskaya RU, Seredenin SB. 2001.

Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test. Bull Exp Biol Med. 131:464-466.

Guillemin GJ., Smythe GA., Veas LA., Takikawa O., Brew B.J. 2003. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia.

Neuroreport. 14: 2311-2315.

Halliday G, Robinson SR, Shepherd C, Kril J. 2000. Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp.

Pharm. Phy. 27: 1-8.

Hashimoto M, Hossain S, Agdul H, Shido O. 2005. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta. 1738:91-98.

Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al. 1992. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 359:322-325.

Haas J, Hagenlocher BS, Biessmann A. and Wildemann B. 2002. Inducible nitric oxide synthase and argininosuccinate synthetase ： co-induction in brain tissue of patients with Alzheimer’s dementia and following stimulation with β-amyloid 1-42 in vitro. Neuroscience Letters. 322：121-125.

Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 5580: 353-356.

Hasegawa M. Smith MJ. Goedert M. 1998. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Letters.

在文檔中樟芝子實體與菌絲體對預防阿茲海默症之功效探討 (頁 112-133)